Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Remoxy Clears Manufacturing Hurdle, Still Needs BE, Abuse-Potential Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

Extended-release oxycodone product has potential for broader abuse-deterrent claims than OxyContin; Pfizer expects to resubmit Remoxy to FDA by mid-2015.


Related Content

Never Surrender: Pain Therapeutics Eyes 2016 Remoxy Filing
Remoxy Development Not ‘Unmitigated Disaster,’ CEO Reassures; Hunt Begins For New Partner
Seeking Guidance On Abuse-Deterrence: Sponsors Fall Short, Congress Urges Action
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Durect Seeks Posidur Partner As It Continues Without A Marketed Drug
Purdue NDA For Oxycodone/Naloxone Combo Tests New FDA Policy
OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible
Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects
Remoxy's Abuse Liability Study May Offer Clues On FDA's Upcoming Opioid Guidance
Now Who Needs a Painkiller? King and Pain Therapeutics Face a Remoxy Setback


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts